Endpoint | Trial Arm | Observed Rate | Model-based Rate (80% CI) |
---|---|---|---|
 | Placebo | 0 of 30 (0%) | 0.0 (---, ---) |
 | 25 mg K-134 | 0 of 29 (0%) | 0.0 (---, ---) |
Resting Tachycardia | 50 mg K-134 | 0 of 30 (0%) | 0.0 (---, ---) |
 | 100 mg K-134 | 0 of 26 (0%) | 0.0 (---, ---) |
 | Cilostazol | 0 of 28 (0%) |  |
 | Placebo | 0 of 20 (0%) | 0.0 (---, ---) |
 | 25 mg K-134 | 0 of 14 (0%) | 0.0 (---, ---) |
Ischemic ECG Changes | 50 mg K-134 | 0 of 19 (0%) | 0.0 (---, ---) |
 | 100 mg K-134 | 0 of 10 (0%) | 0.0 (---, ---) |
 | Cilostazol | 0 of 15 (0%) |  |
 | Placebo | 0 of 32 (0%) | 0.009 (0.002, 0.038) |
 | 25 mg K-134 | 1 of 28 (4%) | 0.018 (0.004, 0.072) |
Discontinuation | 50 mg K-134 | 1 of 32 (3%) | 0.035 (0.009, 0.13) |
 | 100 mg K-134 | 3 of 25 (12%) | 0.12 (0.032, 0.37) |
 | Cilostazol | 1 of 27 (0%) |  |